More than a decade ago, the International Task Force Delphi Panel on Dry Eye identified autologous serum eye drops as a recommended treatment for patients with severe or chronic dry eye symptoms and/or moderate to marked staining.
The therapeutic use of autologous serum eye drops (ASEDs) has since been encouraged in DEWS II and the ASCRS Cornea Committee dry eye treatment algorithms. In short, ASEDs should be considered if education and environmental modifications, artificial tears and earlier-stage treatments, such as punctal occlusion and cyclosporine or lifitegrast, have not been effective,